Summary: Matt Kalaycio, MD, Cleveland Clinic, simplifies initial therapy and monitoring decisions for CML, financial implications for patients treated with TKIs, and treatment choices dictated by payers for patients with specific characteristics. To read more about our host Chadi Nabhan and access exclusive materials and information about guests, visit journalofclinicalpathways.com/podcasts/outspoken-oncology. Journal of Clinical Pathways is the exclusive producer of the Outspoken Oncology podcast.
